French parliament OKs hep C drug rebate scheme
This article was originally published in Scrip
The company rebate mechanism for the expensive new hepatitis C drugs including Gilead's Sovaldi will now be enshrined in French law, after the lower house of the parliament approved the social security financing bill (PLFSS) for 2015.
You may also be interested in...
Drugs for hepatitis C and HIV prevention are causing funding problems for the NHS in England as court battles loom and innovation continues to bring more cost pressures.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.
One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.